Therapeutic Implications of Targeting Energy Metabolism in Breast Cancer

Abstract EN

PPARs are ligand activated transcription factors.

PPARγ agonists have been reported as a new and potentially efficacious treatment of inflammation, diabetes, obesity, cancer, AD, and schizophrenia.

Since cancer cells show dysregulation of glycolysis they are potentially manageable through changes in metabolic environment.

Interestingly, several of the genes involved in maintaining the metabolic environment and the central energy generation pathway are regulated or predicted to be regulated by PPARγ.

The use of synthetic PPARγ ligands as drugs and their recent withdrawal/restricted usage highlight the lack of understanding of the molecular basis of these drugs, their off-target effects, and their network.

These data further underscores the complexity of nuclear receptor signalling mechanisms.

This paper will discuss the function and role of PPARγ in energy metabolism and cancer biology in general and its emergence as a promising therapeutic target in breast cancer.